The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Outpatient Pharmacy Costs PPPM for VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Outpatient Medical Costs PPPM for VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Hospitalization Costs PPPM for VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Costs PPPM for Recurrent VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Outpatient Medical Costs PPPM for Recurrent VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Hospitalization Costs PPPM for Recurrent VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Costs PPPM for Major Bleeding Related VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Outpatient Medical Costs PPPM for Major Bleeding Related VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Hospitalization Costs PPPM for Major Bleeding Related VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Healthcare Costs PPPM for Clinically Relevant Non-Major (CRNM) Bleeding Related VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Outpatient Medical Costs PPPM for CRNM Bleeding Related VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months
Mean All-Cause Hospitalization Costs PPPM for CRNM Bleeding Related VTE Events
Timeframe: From index date until health plan disenrollment, index therapy discontinuation, switch to another anticoagulant or end of study period (up to 72 months); data observed retrospectively over 24 months